Drugs
Tislelizumab
4 articles published between March 2, 2026 and October 10, 2026.
Covered in Science, Body and Policy.
WHAT THE STUDY ACTUALLY SAYSIn a 28-patient single-arm phase 2 study, disitamab vedotin with tislelizumab produced a complete response in 73% of evaluable HER2-positive bladder cancers that could not be resected. There was no comparator.
3 min read
THE DRUG DOCKETBeiGene's PD-1 antibody, added to the HER2 drug zanidatamab and chemotherapy, lifted median overall survival to 26.4 months from 19.2 in the HERIZON-GEA-01 trial. The gain concentrated in the strongest HER2-expressers.
3 min read
THE DRUG DOCKETIn HERIZON-GEA-01, zanidatamab plus chemotherapy raised median progression-free survival to 12.4 months from 8.1 with trastuzumab. A clear survival gain came only when tislelizumab was added.
3 min read
WHAT THE STUDY ACTUALLY SAYSA three-year update of RATIONALE-309 found tislelizumab plus chemotherapy lengthened median progression-free survival to 9.6 months from 7.4. The overall-survival gain was not statistically significant on its own.
3 min read
This page indexes this newspaper’s reporting on Tislelizumab. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.